AAP
NGNE icon

Arax Advisory Partners’s Neurogene NGNE Stock Holding History

Arax Advisory Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$282 Buy
14
+12
+600% +$232 ﹤0.01% 3499
2025
Q4 		$41 Sell
2
-14
-88% -$348 ﹤0.01% 3953
2025
Q3 		$277 Buy
+16
New +$321 ﹤0.01% 3424

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Arax Advisory Partners's NGNE Position: Q1 2026 in Review

Arax Advisory Partners increased its Neurogene (NGNE) stake by 600% in Q1 2026, buying an estimated $232 and bringing the position to 14 shares worth $282. The position accounts for ﹤0.01% of the portfolio, ranked #3499.

Arax Advisory Partners first reported a position in NGNE in Q3 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Arax Advisory Partners held 14 shares of Neurogene worth $282 as of Q1 2026.
  • Arax Advisory Partners bought 12 Neurogene shares in Q1 2026, an estimated $232.
  • Neurogene made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3499 holding.
  • Arax Advisory Partners first reported a position in Neurogene in Q3 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.